A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.
Kim, C., Ryu, D.K., Lee, J., Kim, Y.I., Seo, J.M., Kim, Y.G., Jeong, J.H., Kim, M., Kim, J.I., Kim, P., Bae, J.S., Shim, E.Y., Lee, M.S., Kim, M.S., Noh, H., Park, G.S., Park, J.S., Son, D., An, Y., Lee, J.N., Kwon, K.S., Lee, J.Y., Lee, H., Yang, J.S., Kim, K.C., Kim, S.S., Woo, H.M., Kim, J.W., Park, M.S., Yu, K.M., Kim, S.M., Kim, E.H., Park, S.J., Jeong, S.T., Yu, C.H., Song, Y., Gu, S.H., Oh, H., Koo, B.S., Hong, J.J., Ryu, C.M., Park, W.B., Oh, M.D., Choi, Y.K., Lee, S.Y.(2021) Nat Commun 12: 288-288
- PubMed: 33436577 
- DOI: 10.1038/s41467-020-20602-5
- Primary Citation of Related Structures:  
7CM4 - PubMed Abstract: 
Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal antibodies (mAb) targeting the receptor binding domain (RBD) of the viral spike protein via antibody library constructed from peripheral blood mononuclear cells of a convalescent patient ...